Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Navvi, the cash‑pay digital prescribing platform founded by physicians, today announced the launch of its All‑Specialty Compound Medication Marketplace and a formal call for additional accredited ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...